Multicomponent therapy in patients with pelvic inflammatory diseases

Objective. To compare the outcomes of combination therapy in patients with pelvic inflammatory diseases (PIT)) who use longidase (Bovhyaluronidase azoximer) with those of therapy in patients who do not use of this drug. Subjects and methods. An open-label multicenter comparative study was conducted in 240 patients with acute or exacerbated chronic PID. Group 1 of 170 women used longidasa (Bovhyaluronidase azoximer) 3000-IU suppository once every 3 days in the combination therapy of PID with a total cycle of 20 administrations. Group 2(n = 70) received basic therapy. Results. In Group 1, lower abdominal pain syndrome was relieved much faster and detected in a larger number of patients: only 11 (6.5%) women in the study group continued to notice it after 2 months of treatment while there were 56 (80%) women in Group 2 (p < 0.001). Tenderness was reduced by palpation and cervical traction in all (100%) patients in the study group, while this symptom continued to be noted by 25.7% of women in the basic therapy group (p < 0.001). After performed therapy, the proportion of patients who were observed to have increased uterine dimensions decreased by 56% in Group 1 and only by 15.7% in Group 2 (p < 0.001). During 2-month follow-up, the number of patients with normal white blood cell counts in the cervical canal smear increased more than 3-fold in the study group, whereas 1.03-fold from the baseline in Group 2, and by the end of the follow-up, this was noted in 170(100%) and 59(84.3%) patients in Groups 1 and 2, respectively. Conclusion. longidasa (Bovhyaluronidase azoximer) increases the efficiency of combination treatment for PID, contributes to early improvement of the clinical status of patients, making appropriate use of the drug since the cycle of antibacterial therapy is initiated.

pelvic inflammatory diseases, salpingitis, endometritis, salpingoophoritis, longidasa